Bluebird Bio Inc. (NASDAQ:BLUE) was up 5.2% during trading on Wednesday . The stock traded as high as $47.43 and last traded at $47.33, with a volume of 311,485 shares changing hands. The stock had previously closed at $44.98.

Several equities research analysts have commented on BLUE shares. BTIG Research reaffirmed a “buy” rating and issued a $72.00 price target on shares of Bluebird Bio in a report on Saturday, May 7th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Bluebird Bio in a report on Thursday, May 5th. Maxim Group reaffirmed a “buy” rating and issued a $105.00 price target on shares of Bluebird Bio in a report on Wednesday, April 20th. Goldman Sachs Group Inc. reaffirmed a “buy” rating and issued a $149.00 price target on shares of Bluebird Bio in a report on Monday, April 11th. Finally, Vetr lowered shares of Bluebird Bio from a “strong-buy” rating to a “buy” rating and set a $55.90 price target on the stock. in a report on Wednesday, April 6th. One analyst has rated the stock with a sell rating, six have issued a hold rating and twelve have issued a buy rating to the company’s stock. Bluebird Bio presently has an average rating of “Buy” and an average target price of $96.09.

The firm has a 50-day moving average of $44.11 and a 200-day moving average of $45.65. The company’s market capitalization is $1.78 billion.

Bluebird Bio (NASDAQ:BLUE) last released its earnings results on Wednesday, May 4th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by $0.29. During the same period last year, the firm posted ($0.76) EPS. The company had revenue of $1.50 million for the quarter, compared to analysts’ expectations of $4.50 million. The business’s revenue for the quarter was down 76.2% compared to the same quarter last year. Analysts forecast that Bluebird Bio Inc. will post ($5.90) earnings per share for the current year.

In related news, insider David Davidson sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, July 15th. The shares were sold at an average price of $45.08, for a total value of $45,080.00. Following the completion of the sale, the insider now directly owns 10,600 shares in the company, valued at $477,848. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Philip D. Gregory sold 2,931 shares of the business’s stock in a transaction that occurred on Thursday, June 16th. The shares were sold at an average price of $39.52, for a total transaction of $115,833.12. Following the completion of the sale, the insider now owns 30,069 shares of the company’s stock, valued at $1,188,326.88. The disclosure for this sale can be found here.

Other large investors recently added to or reduced their stakes in the company. Baillie Gifford & Co. increased its stake in Bluebird Bio by 2.1% in the fourth quarter. Baillie Gifford & Co. now owns 4,883,321 shares of the company’s stock worth $313,607,000 after buying an additional 99,617 shares during the last quarter. Jennison Associates LLC increased its stake in Bluebird Bio by 171.3% in the fourth quarter. Jennison Associates LLC now owns 864,314 shares of the company’s stock worth $55,506,000 after buying an additional 545,727 shares during the last quarter. Wells Fargo & Company MN increased its stake in Bluebird Bio by 53.4% in the fourth quarter. Wells Fargo & Company MN now owns 474,832 shares of the company’s stock worth $30,492,000 after buying an additional 165,303 shares during the last quarter. State of Tennessee Treasury Department increased its stake in Bluebird Bio by 45.4% in the fourth quarter. State of Tennessee Treasury Department now owns 191,963 shares of the company’s stock worth $12,328,000 after buying an additional 59,952 shares during the last quarter. Finally, New York State Common Retirement Fund increased its stake in Bluebird Bio by 27.8% in the fourth quarter. New York State Common Retirement Fund now owns 171,022 shares of the company’s stock worth $10,983,000 after buying an additional 37,178 shares during the last quarter.

bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.